Perjeta (Pertuzumab) Global Market Report 2025

Global Perjeta (Pertuzumab) Market Report 2025

Perjeta (Pertuzumab) Global Market Report 2025 – By Type (Human source, Animal source), By Product (Monoclonal Antibody, Biologic Drug), By Indication (Early Breast Cancer, Metastatic Breast Cancer), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

Name: Perjeta (Pertuzumab) Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Perjeta (Pertuzumab) Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Perjeta (Pertuzumab) Global Market Report 2025

Proud Members Of

Perjeta (Pertuzumab) Market Definition

Perjeta (Pertuzumab) is a targeted therapy used in the treatment of certain types of breast cancer. It is a monoclonal antibody that specifically binds to the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells in HER2-positive breast cancer.

The main types of Perjeta (Pertuzumab) are human source and animal source. Perjeta (Pertuzumab) is a monoclonal antibody developed through recombinant DNA technology and produced using mammalian cell lines, not directly from animal sources. However, the use of animal-derived components may occur in the production process. It includes various products such as monoclonal antibodies and Biologic Drugs, identified through various indications such as early breast cancer and metastatic breast cancer. It was distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

Perjeta (Pertuzumab) Market Segmentation

The perjeta (Pertuzumab)market covered in this report is segmented –

1) By Type: Human source, Animal source

2) By Product: Monoclonal Antibody, Biologic Drug

3) By Indication: Early Breast Cancer, Metastatic Breast Cancer

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Perjeta (Pertuzumab) Market Size and growth rate 2025 to 2029: Graph

Perjeta (Pertuzumab) Market Size 2025 And Growth Rate

The perjeta (Pertuzumab) market size has grown rapidly in recent years. It will grow from $935.92 million in 2024 to $1,084.80 million in 2025 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increased adoption in oncology, demand for ADCs, demand for targeted and less toxic treatments, increased inorganic growth, and demand for targeted and personalized medicine.

Perjeta (Pertuzumab) Market Growth Forecast

The perjeta (Pertuzumab) market size is expected to see rapid growth in the next few years. It will grow to $1,932.66 million in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to the rising incidence of breast cancer, rising interest in ADCs for hematologic malignancies, rising incidence of cancer, rising cancer incidence and unmet medical needs, and increasing pharmaceutical R&D for cancer immunotherapy. Major trends in the forecast period include the adoption of biosimilars in oncology, the development of biosimilars and generics, innovation in drug formulations, advances in cancer immunotherapy research, and combination therapies gaining prominence.

Book your 30 minutes free consultation with our research experts

Perjeta (Pertuzumab) Market Driver: Rising Breast Cancer Incidence Driving Growth Of The Herceptin Biosimilars Market

Rising incidence of breast cancer is expected to propel growth of the Perjeta (pertuzumab) market going forward. Breast cancer refers to a disease where malignant cells develop in breast tissue, often originating in the ducts or lobules. The rising incidence of breast cancer can be attributed to lifestyle changes like increased obesity and sedentary habits, as well as improved early detection through widespread screening programs. Perjeta (pertuzumab) is used to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy to improve treatment outcomes. For instance, in October 2023, according to the Ray of Light Wales, a UK-based not-for-profit charity, the number of people living in the UK after a breast cancer diagnosis is estimated at 600,000 and is projected to double to 1.2 million by 2030. Therefore, the rising incidence of breast cancer is driving the growth of the herceptin biosimilars market.

Global Perjeta (Pertuzumab) Market Major Players

Major companies operating in the perjeta (pertuzumab) market include Roche Holding AG

Global Perjeta (Pertuzumab) Market Trend: A Subcutaneous Combination Treatment For HER2-Positive Breast And Colorectal Cancer

The key trend in the Perjeta (pertuzumab) market is focusing on developing technologically advanced solutions, such as subcutaneous combination therapies, to improve patient outcomes and treatment convenience. Subcutaneous combination therapies refer to treatment methods where two or more drugs are combined in a single subcutaneous injection (administered under the skin) to treat a particular condition. For instance, in November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative treatment for subcutaneous administration combines the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing for administration in just 5 to 8 minutes, significantly reducing the time compared to traditional intravenous infusions. Phesgo is indicated for patients with advanced or recurrent HER2-positive colorectal cancer and is the first subcutaneous option for this condition.

Perjeta (Pertuzumab) Market Merger And Acquisition: Zydus Pharmaceuticals And Dr. Reddy’s Laboratories Partner To Enhance Access To Pertuzumab Biosimilar

In June 2024, Zydus Pharmaceuticals, an India-based company that offers pharmaceuticals partnered with Dr. Reddy's Laboratories. The partnership between Zydus Lifesciences and Dr. Reddy’s Laboratories aims to enhance access to a pertuzumab biosimilar for HER2-positive breast cancer patients in India, improving affordability, availability, and patient outcomes through combined distribution efforts. Dr. Reddy's Laboratories is an India-based pharmaceutical company that offers pertuzumab biosimilars.

Regional Outlook For The Global Perjeta (Pertuzumab) Market

North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the perjeta (pertuzumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Perjeta (Pertuzumab) Market?

The perjeta (pertuzumab) market consists of sales of products including herceptin, docetaxel, paclitaxel, and carboplatin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Perjeta (Pertuzumab) Industry?

The perjeta (pertuzumab) market research report is one of a series of new reports from The Business Research Company that provides perjeta (pertuzumab) market statistics, including perjeta (pertuzumab) industry global market size, regional shares, competitors with a perjeta (pertuzumab) market share, detailed perjeta (pertuzumab) market segments, market trends and opportunities, and any further data you may need to thrive in the perjeta (pertuzumab) industry. This perjeta (pertuzumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Perjeta (Pertuzumab) Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	CAGR of 15.5% from 2025 to 2034
Revenue Forecast In 2034	2024
Growth Rate	2019-2024
Base Year For Estimation	2025 - 2029 - 2034
Actual Estimates/Historical Data	Revenue in USD Billion and CAGR from 2025 to 2034
Forecast Period	1) By Type: Human source, Animal source 2) By Product: Monoclonal Antibody, Biologic Drug 3) By Indication: Early Breast Cancer, Metastatic Breast Cancer 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Market Representation	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Segments Covered	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Regional Scope	Roche Holding AG
Country Scope	Request for Sample
Key Companies Profiled	Explore Purchase Options
Customization Scope
Pricing And Purchase Options

1. Executive Summary

2. Perjeta (Pertuzumab) Market Characteristics

3. Perjeta (Pertuzumab) Market Biologic Drug Characteristics

3.1. Molecule Type

3.2. Route Of Administration (ROA)

3.3. Mechanism Of Action (MOA)

3.4. Safety And Efficacy

4. Perjeta (Pertuzumab) Market Trends And Strategies

5. Perjeta (Pertuzumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Perjeta (Pertuzumab) Growth Analysis And Strategic Analysis Framework

6.1. Global Perjeta (Pertuzumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

6.2. Analysis Of End Use Industries

6.3. Global Perjeta (Pertuzumab) Market Growth Rate Analysis

6.4. Global Perjeta (Pertuzumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

6.5. Global Perjeta (Pertuzumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

6.6. Global Perjeta (Pertuzumab) Total Addressable Market (TAM)

7. Global Perjeta (Pertuzumab) Market Pricing Analysis & Forecasts

8. Perjeta (Pertuzumab) Market Segmentation

8.1. Global Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Human source

Animal source

8.2. Global Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monoclonal Antibody

Biologic Drug

8.3. Global Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Early Breast Cancer

Metastatic Breast Cancer

8.4. Global Perjeta (Pertuzumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

9. Global Perjeta (Pertuzumab) Market Epidemiology Of Clinical Indications

9.1. Drug Side Effects

9.2. Incidence And Prevalence of Clinical Indications

10. Perjeta (Pertuzumab) Market Regional And Country Analysis

10.1. Global Perjeta (Pertuzumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. Global Perjeta (Pertuzumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Perjeta (Pertuzumab) Market

11.1. Asia-Pacific Perjeta (Pertuzumab) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Perjeta (Pertuzumab) Market

12.1. China Perjeta (Pertuzumab) Market Overview

12.2. China Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

12.3. China Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

12.4. China Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Perjeta (Pertuzumab) Market

13.1. India Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. India Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. India Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Perjeta (Pertuzumab) Market

14.1. Japan Perjeta (Pertuzumab) Market Overview

14.2. Japan Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. Japan Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. Japan Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Perjeta (Pertuzumab) Market

15.1. Australia Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.2. Australia Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Australia Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Perjeta (Pertuzumab) Market

16.1. South Korea Perjeta (Pertuzumab) Market Overview

16.2. South Korea Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. South Korea Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.4. South Korea Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Perjeta (Pertuzumab) Market

17.1. Western Europe Perjeta (Pertuzumab) Market Overview

17.2. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.4. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Perjeta (Pertuzumab) Market

18.1. UK Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. UK Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. UK Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Perjeta (Pertuzumab) Market

19.1. Germany Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Germany Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Germany Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Perjeta (Pertuzumab) Market

20.1. France Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. France Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. France Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Perjeta (Pertuzumab) Market

21.1. Eastern Europe Perjeta (Pertuzumab) Market Overview

21.2. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Perjeta (Pertuzumab) Market

22.1. North America Perjeta (Pertuzumab) Market Overview

22.2. North America Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. North America Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.4. North America Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Perjeta (Pertuzumab) Market

23.1. USA Perjeta (Pertuzumab) Market Overview

23.2. USA Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. USA Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. USA Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Perjeta (Pertuzumab) Market

24.1. Canada Perjeta (Pertuzumab) Market Overview

24.2. Canada Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. Canada Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. Canada Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Perjeta (Pertuzumab) Market

25.1. South America Perjeta (Pertuzumab) Market Overview

25.2. South America Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. South America Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. South America Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Perjeta (Pertuzumab) Market

26.1. Middle East Perjeta (Pertuzumab) Market Overview

26.2. Middle East Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. Middle East Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. Middle East Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Perjeta (Pertuzumab) Market

27.1. Africa Perjeta (Pertuzumab) Market Overview

27.2. Africa Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Africa Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.4. Africa Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Perjeta (Pertuzumab) Market Competitive Landscape And Company Profiles

28.1. Perjeta (Pertuzumab) Market Competitive Landscape

28.2. Perjeta (Pertuzumab) Market Company Profiles

28.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

29. Global Perjeta (Pertuzumab) Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Perjeta (Pertuzumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Perjeta (Pertuzumab) Market

32. Recent Developments In The Perjeta (Pertuzumab) Market

33. Perjeta (Pertuzumab) Market High Potential Countries, Segments and Strategies

33.1 Perjeta (Pertuzumab) Market In 2029 - Countries Offering Most New Opportunities

33.2 Perjeta (Pertuzumab) Market In 2029 - Segments Offering Most New Opportunities

33.3 Perjeta (Pertuzumab) Market In 2029 - Growth Strategies

33.3.1 Market Trend Based Strategies

33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations

34.2. Currencies

34.3. Historic And Forecast Inflation Rates

34.4. Research Inquiries

34.5. The Business Research Company

34.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Perjeta (Pertuzumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Perjeta (Pertuzumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Perjeta (Pertuzumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Asia-Pacific, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Asia-Pacific, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Asia-Pacific, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: China, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: China, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: China, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: India, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: India, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: India, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: Japan, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: Japan, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Japan, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Australia, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Australia, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Australia, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: South Korea, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: South Korea, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: South Korea, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Western Europe, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Western Europe, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Western Europe, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: UK, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: UK, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: UK, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Germany, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Germany, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Germany, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: France, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: France, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: France, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Eastern Europe, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Eastern Europe, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Eastern Europe, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: North America, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: North America, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: North America, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: USA, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: USA, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: USA, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Canada, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Canada, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Canada, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: South America, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: South America, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: South America, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Middle East, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Middle East, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Middle East, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Africa, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Africa, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: Africa, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: Roche Holding AG Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Perjeta (Pertuzumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Perjeta (Pertuzumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Perjeta (Pertuzumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Asia-Pacific, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Asia-Pacific, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Asia-Pacific, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: China, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: China, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: China, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: India, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: India, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: India, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: Japan, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: Japan, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Japan, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Australia, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Australia, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Australia, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: South Korea, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: South Korea, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: South Korea, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Western Europe, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Western Europe, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Western Europe, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: UK, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: UK, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: UK, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Germany, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Germany, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Germany, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: France, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: France, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: France, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Eastern Europe, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Eastern Europe, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Eastern Europe, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: North America, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: North America, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: North America, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: USA, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: USA, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: USA, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Canada, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Canada, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Canada, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: South America, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: South America, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: South America, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Middle East, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Middle East, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Middle East, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Africa, Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Africa, Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: Africa, Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: Roche Holding AG Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the alpha mannosidosis research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the oral biologics and biosimilars market research report 2022 with industry size, share, segments and market growth

Metastatic Cancer Drugs Global Market Report 2025 – By Drug Class (HER2 Inhibitors, Immune Checkpoints Inhibitors, PARP Inhibitors, Kinase Inhibitors, Other Drug Class), By Cancer (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, Other Cancers), By Treatment (Chemotherapy, Immunotherapy, Hormonal Therapy, Surgery, Other Treatments), By Route Of Administration (Intravenous, Intramuscular, Oral, Other Routes Of Administration), By End-Users (Hospitals, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Gastric Cancer Drugs Global Market Report 2025 – By Type (Imatinib, Trastuzumab, Other Types), By Route of Administration (Oral, Parenteral), By End User (Hospitals, Clinics, Cancer Specialty Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Kidney Cancer Drugs Global Market Report 2025 – By Type (Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)), By Product (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Other Products), By End Users (Hospitals, Clinics, Research Center, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Ovarian Cancer Drugs Global Market Report 2025 – By Tumor Type (Epithelial Ovarian Cancer, Germ Cell Ovarian Cancer, Stromal Cell Ovarian Cancer), By Drug Type (Alkylating Agents, Mitotic Inhibitors, VEGF/VEGFR inhibitors, PARP inhibitors, Other Drug Types), By Distribution Channel (Hospital Pharmacies, Drug Stores, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Pancreatic Cancer Drugs Global Market Report 2025 – By Type (Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs), By Drug Combination (Single, Double, Triplet, Quadruplet), By End User (Hospital Pharmacies, Retail Pharmacies, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Cervical Cancer Drugs Global Market Report 2025 – By Cancer Type (Squamous Cell Cancer, Adenocarcinoma), By Drug Type (Avastin, Bevacizumab, Bleomycin, Blenoxane, Other Drug Types), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Colorectal Cancer Drugs Global Market Report 2025 – By Type (Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL– Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators), By Class (Immunotherapy, Chemotherapy, Other Classes), By Distribution Channels (Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Skin Cancer Drugs Global Market Report 2025 – By Type (Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma), By Drug Class (Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs), By End Users (Hospitals, Cancer Research Centers, Clinics) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Perjeta (Pertuzumab) market?

Perjeta (pertuzumab) is a targeted therapy used in the treatment of certain types of breast cancer. It is a monoclonal antibody that specifically binds to the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells in HER2-positive breast cancer. For further insights on the Perjeta (Pertuzumab) market, request a sample here

How will the Perjeta (Pertuzumab) market drivers and restraints affect the market dynamics? What forces will shape the Perjeta (Pertuzumab) industry going forward?

The Perjeta (Pertuzumab) market major growth driver - Rising Breast Cancer Incidence Driving Growth Of The Herceptin Biosimilars Market. For further insights on the Perjeta (Pertuzumab) market, request a sample here

What is the forecast market size or the forecast market value of the Perjeta (Pertuzumab) market?

The Perjeta (Pertuzumab) market size has grown strongly in recent years. The perjeta (pertuzumab) market size has grown rapidly in recent years. It will grow from $935.92 million in 2024 to $1,084.80 million in 2025 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increased adoption in oncology, demand for ADCs, demand for targeted and less toxic treatments, increased inorganic growth, and demand for targeted and personalized medicine. The perjeta (pertuzumab) market size is expected to see rapid growth in the next few years. It will grow to $1,932.66 million in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to the rising incidence of breast cancer, rising interest in ADCs for hematologic malignancies, rising incidence of cancer, rising cancer incidence and unmet medical needs, and increasing pharmaceutical R&D for cancer immunotherapy. Major trends in the forecast period include the adoption of biosimilars in oncology, the development of biosimilars and generics, innovation in drug formulations, advances in cancer immunotherapy research, and combination therapies gaining prominence. For further insights on the Perjeta (Pertuzumab) market, request a sample here

How is the Perjeta (Pertuzumab) market segmented?

The perjeta (pertuzumab)market covered in this report is segmented –
1) By Type: Human source; Animal source
2) By Product: Monoclonal Antibody; Biologic Drug
3) By Indication: Early Breast Cancer; Metastatic Breast Cancer
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies For further insights on the Perjeta (Pertuzumab) market, request a sample here

Which region has the largest share of the Perjeta (Pertuzumab) market? What are the other regions covered in the report?

Who are the major players in the Perjeta (Pertuzumab) market?

Major companies operating in the perjeta (pertuzumab) market include Roche Holding AG . For further insights on the Perjeta (Pertuzumab) market, request a sample here.

What are the key trends in the Perjeta (Pertuzumab) market?

Major trends in the Perjeta (Pertuzumab) market include A Subcutaneous Combination Treatment For HER2-Positive Breast And Colorectal Cancer. For further insights on the Perjeta (Pertuzumab) market, request a sample here.

What are the major opportunities in the Perjeta (Pertuzumab) market? What are the strategies for the Perjeta (Pertuzumab) market?

For detailed insights on the major opportunities and strategies in the Perjeta (Pertuzumab) market, request a sample here.

How does the Perjeta (Pertuzumab) market relate to the overall economy and other similar markets?

For detailed insights on Perjeta (Pertuzumab)'s relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Perjeta (Pertuzumab) industry?

For detailed insights on the mergers and acquisitions in the Perjeta (Pertuzumab) industry, request a sample here.

What are the key dynamics influencing the Perjeta (Pertuzumab) market growth? SWOT analysis of the Perjeta (Pertuzumab) market.

For detailed insights on the key dynamics influencing the Perjeta (Pertuzumab) market growth and SWOT analysis of the Perjeta (Pertuzumab) industry, request a sample here.